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ABSTRACT Rifazone-82 (R-82), a new rifamycin derivative, is shown to
preferentially inhibit the growth of virus-transformed chick cells in
culture. Macromolecular synthesis and glucose uptake of transformed cells
are also appreciably decreased in the presence of low concentrations of
R~82 where the normal cells appear unaffected. While R-82 is shown to be
a selective inhibitor of RNA-directed DNA polymerase ~ vitro, its action
on the growth of transformed cells may involve some other mechanism.
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Introduction
Rifamycin and its derivatives have been shown to inhibit focus forma-
tion by RNA tumor viruses in various cell types in culture (1-5). The ~
vitro demonstration that RNA-directed DNA polymerase (RDP) is inhibited
by the action of some of these derivatives (6-13) has raised the possi-
bility that the drugs may inhibit focus formation by inhibiting RDP
activity. Smith et a1. have shown recently that those rifamycin deriva-
tives that are toxic to leukemic human leucocytes are also those that
inhibit RDP best iR vitro (14).
Rifampicin. a well known derivative of rifamycin has been shown to
inhibit the replication of vaccinia virus in tissue culture when added at
very high levels (> 100 ~g/ml) (15.16) and to reduce the incidence of
Adenovirus-induced tumors in male hamsters (16). In chick cells it has
been argued that rifampicin a) inhibits focus formation by Rous sarcoma
virus (1), b) has no effect on transformation, as it is toxic to both
normal and transformed cells (17). and c) is preferentially toxic to
transformed cells (20). Variation in culture conditions, serum concentra-
tion, and ceT1 density undoubtedly playa role in such contradictory
findings. For example, whether or not amphotericin B is present in culture
medium, may drastically change the result of focus inhibition (4.19). Fur-
thermore, the high concentration of rifampicin used in these experiments
(20-80 pg/ml) under some conditions is quite toxic to normal cells and
makes interpretation of these data very difficult. Rifampicin itself has
little or no effect on RDP activity ~ vitro at concentrations used in
tissue culture studies (7,17,20). We have tested several new rifamycin
derivatives synthesized in this laboratory which have been shown to be
-3-
inhibitors of RDP in vitro and inhibitors of focus formation in vivo in
other cell systems (4-6). In addition, we have tested Rifazone-82 (R-82),
a new rifamycin which is to date the most selective inhibitor of viral RDP
1'n vitro (6,21). We find that at low concentrations (3-10 ~g/ml), R-82
can selectively inhibit the growth of transformed cells and prevent focus
formation while allowing the normal cell growth and function to continue.
Materials and Methods
Growth of Cell Cultures. Primary cultures were prepared from 10-day
old C/O or C/B type SPF chick embryos as described previously (23,24),
except that Amphotericin B (Fungizone) was eliminated at this point (25).
The cells were seeded in Medium 199, which was supplemented with tryptose
phosphate broth (2%), calf serum (1%), and heated chicken serum (1%). The
medium was changed on day 3. Secondary cultures were prepared 4 days after
the primary seeding by· trypsinization of primary cultures and were seeded
at the desired cell concentration in 60 or 35 mm petri dishes. An addi-
tional 1 mg/m1 of glucose was added to the medium at tllis time, bringing
the final concentration of glucose to 11.00 mM, and calf serum concentra-
tion was raised to 2%. For studies with transformed cultures, half the
cells of a single embryo were infected 4 hours after primary seeding with"
4 x 105 focus forming units of SR-RSV or B-RSV. Secondary cultures were
prepared as above.
Focus Assay. Assays were performed essentially as described (22), wjth
slight modifications~ We found that gentle removal of the agar on day 4 or
5 and addition of either liquid medium or another agar overlay enhances the
visibility of foci. Four hours after seeding secondary normal cells at
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2.5 x 106 per 60 rnm dishes, medium was removed and cells were exposed to
the appropriate dilution of virus in 0.5 ml for 1 hr. The virus was then
removed, the monolayer rinsed, and appropriate concentrations of drugs
were added together with 1 ~g/ml Fungizone in 0.5 ml of medium 199.
Rifamycins were dissolved in dimethyl sulfoxide (DMSO) so that all
cultures had a final concentration of 0.1% DMSO. Thirty minutes later
the derivatives were removed and cells were overlaid with agar-medium
containing the same concentration of the derivatives. In experiments
where the rifamycins were added at a later time, the agar layers of control
cultures were removed and replaced with agar containing DMSO at the same
time. A known titre of SR virus stock accompanied all assays.
Measurements of the Rate of DNA and Protein Synthesis and Glucose
Uptake. Radioactive assays were performed as previously described (25,26).
All radioactive compounds were purchased from New England Nuclear.
Rlf!!ycin Derivatives. These were synthesized as previously described
(20,21), •
Resul ts
Focus Fonnation
When foci were scored on day 8 and 6 for SR-RSV or B-RSV respectively,
there was a marked inhibition of the number of foci in the presence of
rffazone-82 (R-82) (Table I). Ten ~g/ml dimethYlbenzyl rifampicin (DMB)
also caused appreciable inhibition with SR-RSV. Rifazacyclo-16 (RC-16),
previously shown to be an inhibitor of MSV focus formation on UC1-B cells
(4) W~., nnt vo,,"v 0ff0t"t,'\lo in "'h,'",J, "'ell'"i .... ••_- -,.,..J .... '-""""""'"' 1'1"'" ..... " "" II~. Rifampicin, at 20 ~g/ml, had
no effect on focus formation. The few remaining foci in the presence of the
effective rifamYcins were usually much smaller than the control foci (Fig. 1).
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When the foci were scored again 3 days later, the apparent inhibition had
decreased in almost all cases suggesting an inhibition of the growth of the
focus once it had been formed (Table I).
a. Normal Cells at High Cell Density. Under the condition of agar
assay (more than 1 x 105 normal cells/cm2), 10 ~g/ml of R-82 had no effect
on the growth properties of normal cells (Fig. 2). DMB, however, was toxic
under these conditions. To avoid the complication of toxicity under assay
conditions, we chose to work with R-82 alone. The pronounced inhibition of
focus formation by R-82, therefore, is not due to toxicity to the normal
cells in the monolayer. As a further control, the normal cells from the
uninfected areas of drug treated cultures were removed from under agar
and replated. They showed normal growth properties when compared to control
cultures re-grown after agar removal and were morphologically normal as well.
b. Comparison of Normal and Transformed Cells at Low densities. When
cells were seeded at lower cell densities (2 x 104 cells/cm2) they were more
sensitive to R-82 than cells at the higher cell densities (compare Figs. 2
and 3a). Howwever, at comparable cell densities and growth rates, trans-
formed cells were always much more sensitive than normal cells (Fig. 3).
While normal cells were unaffected by 5 ~g/ml of R-82, the growth of trans-
formed cells was considerably inhibited by 3 ~g/ml of R-82 after 48 hr
{Fig. 3c}. Three days after addition of 5 ~g/ml R-82, the morphology and cell
number were still the same in untreated and treated normal cultures (Fig.
4A, B). The R-82 treated transformed cells, however, were drastically
reduced in number and the remaining cells were either vacuulated or had a
nonmal morphology (Fig. 40). DNA synthesis as measured by r3H]-thymidine
incorporation (26) and uptake of glucose as measured by r3H]-2 desoxYglucose (26)
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showed the same pattern of preferential sensitivity to R-82 (Table II).
The soluble pool of r3H]-thymidine was not affected by the presence of
R-82. The rate of protein synthesis as measured by [3HJ-leucine incor-
poration into the acid insoluble pool was the least sensitive to the action
of R-82, although transformed cells were still more affected (Table lIb).
Effect of R-82 on Previously Formed Foci
To understand to what degree this preferential toxicity to transformed
cells could explain the focus inhibition, two kinds of experiments were
performed. In one series of focus assays, 10 ~g/ml R-82 was added 1 hr
after infection, resulting in more than 90% inhibition of focus number
after 8 days. If the action of R-82 was solely on inhibiting the
initiation of transformation one would expect that addition of R-82 2 days
later would have no effect on the number of foci produced. In fact,
when R-82 was added 2 days after infection there was still more than 40%
inhibition of the foci· if scored on day 8. Furthermore, the remaining
foci were smaller than control (compare Fig. lC and D), and the percent
inhibition decreased to about 10% by day 11 when the f)ci became quite
visible. This experiment indicated to us that a large proportion of the
focus inhibition observed (Table I) may be attributed to the preferential
toxicity of transformed cells to R-82 in addition to any inhibition of
initiation of transformation.
In a second series of experiments B-RSV foci were allowed to develop,
until they were visible (5 days). The agar was then removed gently and
complete medium was added with or without 10 ~g/ml of R-82• The foci
continued to grow with a measurable rate in control cultures (Fig. 5A, B,
Fig. 6). The removal of the agar resulted in a "necrotic" focus as the
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piled up transformed cells in the center of the focus were lost to the
medium (Fig. 5B). The growth of the foci after the addition of 10 ~g/ml
R-82, however, was virtually arrested (Fig. 5C, D, Fig. 6). It has been
shown previously that 48 hr after seeding, the normal chicken cells seeded
at high density are no longer susceptible to transformation by B-RSV (22).
The focus of B-RSV, therefore, is comprised essentially of the progenies
derived from the initially transformed cell. Indeed, we observed no addi-
tional foci in control cultures, despite the fact that virus is released
into the medium after agar removal. Tnus the lack of focus growth in the
presence of R-82 is due to inhibition of transformed cell growth rather
than an inhibition of secondary infection.
Mixed Cultures
Two experiments were performed in which 50% normal and 50% transformed
cells. were plated and allowed to grow in the presence and absence of R-82
(5 ~g/ml) for 3 days .. In the first experiment, where the cells were plated
at a low density (1 x 104 cells/cm2), cells grown in the absence of R-82
appeared to be completely transformed (Fig. 7A), whilr cultures grown in
the presence of R-82 appeared to be largely normal by the end of the 3-day
period (Fig. 78). In the second experiment, where the cells were plated
at· a higher density (5 x 104 cells/cm2), cells grown without R-82 appeared
to be completely transformed as expected. The cells with R-82 present,
however, were still in a monolayer and the majority of cells were normal,
although dispersed transformed cells could be seen in the culture. Con-
sistent with previously described results, these mixed culture experiments
indicate a preferential inhibition and/or killing of transformed cells.
furthermore, they might suggest an additional role of R-82 in preventing
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secondary infection by inactivating the virus itself, Whether the presence
of R-82 in these experiments selects for normal cells by killing trans-
formed cells, or whether it actually causes a reversion toward a normal
morphology, is a question currently under investigation.
DISCUSSION
The selective inhibition and/or destruction of neoplastic cells while
the normal cell growth and function continues, is a general aim of cancer
chemotherapy. We have shown that rifazone-82, a specific inhibitor of RDP
(21) also inhibits the growth of virus-transformed cells in tissue culture
without appreciable side effects to normal cell growth. Preferential inhibi-
tion of transformed cells has been reported for rifampicin previously (18).
However, rifamipicin does not inhibit RDP appreciably (9) and the dosage
needed for focus inhibition (more than 20 ~g/ml) is toxic to normal chick
cells"in our hands.
There are a number of possible explanations for this increased toxicity
of R-82 to the transformed cells. 1) There is abundant evidence that cancer
cells in general have altered permeability (27) and al'ered membrane
properties (28), factors which could account for the observations described
here. Once the nature of these differences is understood they may further
be"exploited to synthesize new derivatives which can cross the membrane of
specific tumor cells more readily. 2) The drug may act partially by pre-
venting transformation through inhibition of reverse transcriptase (12).
If a continuing involvement of this enzyme in the growth of transformed
cells 1s postulated, the additional inhibitory action of R-82 on the growth
of transfonmed cells may be explained. 3} Alternatiyely, R-82 may be
inhibiting an as yet unknown enzyme function(s) which might be essential
-9-
to the growth of transformed cells. These possibilities are not mutually
exclusive. The additional action of R-82 on the infectivity of the virus
itsel(hO~ldalso be investigated (12). To what extent a change in per-
meability of transformed cell membrane is responsible for the observed
effects will be studied by use of radioactive derivatives. The effect of
R~82 and other rifamYcin derivatives in various cell systems and animals
is under investigation.
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Abbreviations used: R-82 or Rifazone 82, rifaldehyde-N,N-di-n-octyl-
hydrazine-hydrazone; RDP, RNA-directed DNA polymerase; RSV, Rous sarcoma
virus; B-RSV, Bryan high titre strain of RSV; SR-RSV, Schmidt-Ruppin
sub-group A strain of RSV; Rif, Rifampicin; DMB, 21 ,6 l-dimethyl-4I-benzyl-
4~-desmethYlrifampicin; DMSO, dimethYl sulfoxide.
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Table I
Focus Inhibition - %of Control
Schmidt-Ruppin*
Day 8 Day 11
Cont (DMSO) 100 (80~20)t 100 (85~20)
Rif 20 Im1 100 ~ 10 100 ~ 10
RC-16 10 Iml 75 ~ 10 85 ! 10
DMB 1 Iml 50 ! 7 85 ! 8
DNB 10 Iml 0-2 10 ! 6
R..82 1 Iml 90 ! 10 90 ~ 10
R-82 5 Iml 40 ~ 10 70 ! 15
R-82 10 Im1 0-1 15 ~ 10
+Bryan
Day 6
100 (70!20)
100 ! 10
90 ~ 10
45 ! 10
10 :! 8
Day 9
100 (70!20)
laO! 8
95 ~ 10
70 ! 15
20 "!: 10
50-100 focus forming units of Schmidt-Ruppin (SR) subgroup A or
Bryan strain of Rous sarcoma virus were assayed under agar as described
in Methods. The foci were scored on day 8 and 11 for SR and on days 6
and 9 for the Bryan strains. Amphotericin B (1 ~g/m1) was present
throughout the focus assay, even though at best it improved the inhibi-
tion by only 10%.
*.Average of 6 experiments
+ Average of 4 experiments
t The number in parenthesis indicates the actual number of foci
which was set equal to 100.
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Table IIa
[3H]~Thymidine Incorporation
% of control after 48 hr
pg of drug per ml
0 3 5 10 15 20
N 100 (38600)* 100 100 74 39 20
T 100 (44600) 70 64 51 28 4
* DPM/mg protein. Average of 3 experiments.
Procedure was as described in Fig. 3 and Methods.
Table IIb
[3H]~Leucine Incorporation and [3H] 2-Deoxyglucose Uptake
Leucine 2-DG
N T N
%of control after 48 hr
T
Control 100 (32100)* 100 (42900) 100 (43900) 100 (98100)
3 g/m1 100
. ,
.5 g/m1 100
10 g/m1 85
100
88
t
108
105
85
72
53
42
* The numbers in parentheses represent DPM/mg protein.
t Too few cells left for de.termination. Average of triplicate samples
of cne experiment.
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Figure Legends
Fig. 1. Focus formation in the presence and absence of R-82.
Focus of SR-RSV on day 8. A) in 0.1% D~1S0, B) in the presence of R-82
(10 ~g/ml) added 1 hr after virus infection. C) in 0.1% DMSOj the agar
overlay was replaced after 2 days. D) in the presence of R-82 (10 ~g/ml)
added 2 days after virus infection.
Fig. 2. Growth of high density normal cells in the presence of rifamycin
derivatives. Normal cells were plated at 1 x 105/cm2 in the presence
or absence of the chemicals as described in Methods. Average of 4 measure-
ments .
Fig. 3. Growth of normal and RSV-transformed cells in the presence of R-82.
Normal and SR-transformed cells were seeded at 2 x 104 cells/cm2 4 days
after primary seedings. The medium contained either DMSO or ~-82 (3. 5.
10 and 20 ~g/ml). Cells were counted on successive days in triplicate.
Fig. 3C is the percent cells left on the dish after 48 hr
(taken from 3A and 38; the cell number in control cultures was set equal
to 100).
Fig ... -4. - Morphology of normal and transformed cells in the presence of R-82.·, ,
Legend as in Fig, 3. except that cells were seeded at 1.5 x 104 cells/cm2
and medium was changed on day 2. Control and treated cultures (5 ~g/ml R-82)
were photographed 3 days after seeding. A and B, nonnal 'cells in the absence
and presence of R-82. C and 0, transformed cells in the absence and presence
of R-8Z'
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Fig. 5. Arrest of focus growth after addition of R-8Z'
Two sets of focus assay plates of B-RSV were allowed to develop until foci
were visible (5 days). The agar overlay was then removed and replaced with
regular medium containing 0.1% DMSO or R-82 (10 ~g/ml in 0.1% OMSO).
Visible foci were encircled with black pen and numbered and they were then
photographed on successive days. Arrows indicate the boundary of focus in
each case. A, control focus 1 hr after addition of liquid medium; B, the
same focus as in A, 82 hr later; C, focus 1 hr after addition of liquid
medium and R-82 (10 ~g/ml); 0, the same focus as in C, 82 hr later.
Fig. 6. The rate of growth of previously formed foci in the presence or
absence of R-82.
Experiment was performed as described in Fig. 5. The area under the foci
was estimated by use of a planimeter. Each curve is the average of 3 foci.
Fig. 7. Morphology of mixed cultures in the presence and absence of R-82.
50% nonmal and 50% transformed cells were seeded at a total population of
1 x 104 cell/cm2. The pictures were taken 3 days after seeding. A), culture
with DMSO. B), culture with R-82 (5 ~g/ml).
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